A stability-indicating HPLC procedure for determination of diltiazem hydrochloride in extemporaneously compounded oral liquids - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A stability-indicating HPLC procedure for determination of diltiazem hydrochloride in extemporaneously compounded oral liquids
A stability-indicating procedure for the determination of diltiazem hydrochloride in diltiazem hydrochloride (HCl) oral suspension and diltiazem HCl oral suspension, sugar free, is reported. Both suspensions were prepared from commercially available diltiazem HCl powder in a 1:1 (v/v) mixture of vehicle for oral solution and vehicle for oral suspension, and 1:1 (v/v) mixture of vehicle for oral solution, sugar free, and vehicle for oral suspension.


Pharmaceutical Technology Europe


Results and discussion


Table 3 Accuracy and precision results for diltiazem HCl in diltiazem HCl oral suspension (Formula 1) and diltiazem HCl oral suspension, sugar free (Formula 2).
Specificity. To establish that there was no interference from other vehicle components or degradation products in the stability-indicating ability of the procedure, individual optically active vehicle ingredients, both placebos and suspensions, were injected into the HPLC. Figures 1 and 2 depict typical chromatograms of the assay preparations of diltiazem HCl oral suspension and diltiazem HCl oral suspension, sugar free, respectively. The diltiazem peak was well resolved from the vehicle ingredients and the main degradation product, desacetyl diltiazem.


Figure 4
To further evaluate the specificity of the procedure forced degradation studies were performed. For photochemical and thermal degradation studies, a 5 mL aliquot of each suspension and placebo was subjected to short-wave and long-wave ultraviolet and visible light and to 90 C for 24 h. Acid-, base- and oxidizer-treated samples were prepared by mixing a 5 mL aliquot of each suspension and placebo with 5 mL of 0.1 N hydrochloric acid, 0.1 N sodium hydroxide and 3% hydrogen peroxide and letting them sit at ambient temperature for 24 h (Formula 1 was exposed only to base for 1 h). After degradation treatment, samples were allowed to cool to room temperature, if necessary. Acid- and base-treated samples were neutralized with an appropriate amount of 0.1 N sodium hydroxide and 0.1 N hydrochloric acid, respectively. All samples were prepared and analysed using the sample preparation procedure and the chromatographic conditions described in the experimental section. Diode array detection was employed for spectral purity analysis of the diltiazem peak in the stress samples over a range of 200–700 nm. The diltiazem peak was considered spectrally pure when the peak purity value was greater than 0.996. The area responses of diltiazem HCl in the stress samples were compared to those in the untreated samples and reported as percent diltiazem HCl concentration remaining. The results of the forced degradation study for both suspensions, including the peak purity values obtained by using the capability of the chromatographic software ChemStation, are shown in Tables 1 and 2.


Figure 5
Both suspensions significantly degraded under all stress conditions except UV and visible light exposure. The greatest number of additional peaks, 10, was produced when an aliquot of either suspension was stressed with hydrogen peroxide solution. A typical chromatogram of a hydrogen peroxide–stressed suspension sample is shown in Figure 3. None of the detected additional peaks displayed retention times that overlapped the diltiazem peak under any stress condition. All of the diltiazem peaks had a peak purity value greater than 0.996 except Formula 1, which under basic stress conditions for ~1 h yielded a diltiazem peak purity of 0.9792. Adjustments in the HPLC conditions did not improve the diltiazem peak purity in the base-stressed sample. Also, there was no significant degradant peak observed at the retention time of diltiazem in the stressed placebos. Despite various stresses and degradation conditions the diltiazem peaks demonstrated spectral purity, which supports the use of this procedure to monitor the stability of diltiazem HCl oral suspension and diltiazem HCl oral suspension, sugar free.


Figure 6
Linearity. The range of the assay procedure was set at 70–130% of the diltiazem HCl label claim in the suspensions. Linearity of the detector response was investigated at five levels from 70% to 130% (set 1) and at seven levels covering a wider range from 0.1% to 200% (set 2) of the nominal assay sample concentration. A single injection of each of the linearity solutions was made and plots of peak area versus concentration were constructed. Linear regression was performed and the correlation coefficients were calculated. The correlation coefficients were 0.9995 (set 1) and 1.0000 (set 2) (desired correlation coefficient: ≥0.999). The percentage of the intercept relative to 100% analyte was in the range 2% which is considered negligible.7,8 The range of the procedure was determined to be 0.0012–2.41 μg/mL (0.1%–200% of the nominal sample concentration of 1.2 mg/mL). Further ranges may be applicable but were not investigated.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology Europe,
Click here